Boston, U.S.A. – March 29, 2022. Alloplex Biotherapeutics Inc. has, today, welcomed Jennifer Brown, MD, PhD  to its Scientific Advisory Board as a Scientific and Clinical Advisor.

Dr. Brown, the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and the Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts, is internationally known  for her clinical-translational research in CLL.

Dr. Brown’s research interests include understanding the genomics of CLL, the understanding of the many biochemical and molecular facets leading to disease and the development of novel targeted therapeutics for CLL including understanding resistance mechanisms. Dr Brown also leads the CLL clinical trials effort at Dana-Farber.

In 2014 she was the recipient of two prestigious awards from Dana-Farber Cancer Institute: the Clinical Innovation Award, as well as the George Canellos Award for Excellence in Clinical Investigation and Patient Care.

“I am pleased to be joining the Alloplex SAB at such a key point in the translational development of SUPLEXA therapeutic cells.” said Dr. Brown. “Despite the recent advances in CLL therapy, patients are still relapsing and we are in need of additional effective therapies.  SUPLEXA cells have unique characteristics with the potential to contribute substantially to the control of hematologic malignancy,” she said.

Commenting on the appointment, Dr. Frank Borriello, Scientific Founder & CEO of Alloplex Biotherapeutics, said “It is an honor to welcome Dr. Jennifer Brown to the Alloplex Scientific Advisory Board. Her knowledge and experience treating CLL will be invaluable to Alloplex as we embark on our first-in-human SUPLEXA trial,” he said.

---

About Dr. Brown

Dr. Jennifer Brown is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and the Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts.

Dr. Brown completed a B.S. and M.S. simultaneously in molecular biophysics and biochemistry (MB&B) at Yale, graduating summa cum laude with distinction in MB&B.  She proceeded to Harvard Medical School where she received her MD and PhD in molecular genetics in 1998 and was awarded the James Tolbert Shipley Prize for research accomplishment in the graduating class.  She then served as an intern and resident in Internal Medicine at Massachusetts General Hospital followed by fellowship in Hematology and Medical Oncology at the Dana-Farber Cancer Institute. Dr. Brown joined the faculty of DFCI and Harvard Medical School in 2004, where she has an active clinical-translational research program in CLL. 

She has been instrumental in the clinical development of both idelalisib and ibrutinib, leading to their regulatory approvals in CLL. In the area of genomics, she has contributed to the description of the somatic mutation profile of CLL, and is now particularly interested in the implementation of genomic technology in the clinic, including for prognosis and targeted therapy.  To date, she has published over 250 papers in the scientific literature, predominantly in CLL.

---

About Alloplex Biotherapeutics, Inc.

Alloplex Biotherapeutics is a clinic-ready company focused on developing SUPLEXA; a potential first-in-Alloplex Biotherapeutics is a clinic-ready company focused on developing SUPLEXA for the treatment of cancer patients. The privately-held company was established in 2016 by Scientific Founder and CEO, Dr. Frank Borriello, MD, PhD.

SUPLEXA is a potential first-in-class, autologous, pan cancer-cellular therapy. SUPLEXA, made from the patient’s own immune cells, and is comprised primarily of cells with known anti-tumor killing cells such as NK cells, NKT cells and T cells. SUPLEXA therapeutic cells are manufactured ex vivo over a 2-week period and administered intravenously.

The company received regulatory permission to conduct a Phase 1 clinical trial for SUPLEXA therapeutic cells in Australia in January 2022. The trial will commence in April 2022.